...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and mu-opioid receptor agonism
【24h】

Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and mu-opioid receptor agonism

机译:糖尿病周围神经痛/孤啡肽FQ受体和μ阿片受体激动剂选择性抑制糖尿病性多神经病大鼠的机械性痛觉过敏

获取原文
获取原文并翻译 | 示例
           

摘要

Peripheral receptors may contribute to the effects of systemically administered centrally available analgesics. In the present study, we analysed the effect of local peripheral injection of the nociceptin/orphanin FQ peptide (NOP) receptor agonist Ro65-6570 and compared it to the mu-opioid peptide (MOP) I eceptor agonist morphine in streptozotocin-induced diabetic polyneuropathy in rats. Ro65-6570 and morphine were injected intraplantarly into the hind paw of diabetic rats, and mechanical withdrawal thresholds were determined in both paws (ipsi- and contralateral to the injection site). Ro65-6570 in the dose range of 7.1-71.4 nmol/animal showed antihyperalgesic effects with maximal efficacy of 57.1 +/- 15.4% maximal possible effect (MPE) at the close of 23.8 nmol/animal. Intraplantar administration of morphine showed dose-dependent antihyperalgesic effects in the dose range of 25.8-257.8 nmol/animal in a similar efficacy range with a maximal efficacy of 76.0 +/- 12.1% MPE at the dose of 257.8 nmol/animal. Both compounds did not induce overt confounding side effects across the tested dose range. The NOP receptor antagonist J-113397 and the MOP receptor antagonist naloxone, intraplantarly co-administered with the respective agonists, selectively and completely prevented the antihyperalgesic action of the respective NOP and MOP receptor agonist. These results indicate that the activation of peripheral NOP and MOP receptors by Ro65-6570 and morphine, respectively, mediated antihyperalgesic effects in rats with diabetic polyneuropathy. (C) 2015 Elsevier By. All rights reserved.
机译:外周受体可能有助于全身使用的集中镇痛药的作用。在本研究中,我们分析了局部外周注射痛觉敏肽/孤儿蛋白FQ肽(NOP)受体激动剂Ro65-6570的作用,并将其与μ阿片肽(MOP)I受体激动剂吗啡在链脲佐菌素诱发的糖尿病多发性神经病中进行了比较在大鼠中。将Ro65-6570和吗啡注射入糖尿病大鼠的后爪足底,并测定两只爪(注射部位的同侧和对侧)的机械退缩阈值。 Ro65-6570在7.1-71.4 nmol /动物的剂量范围内显示出抗痛觉过敏作用,最大功效为57.1 +/- 15.4%,在23.8 nmol /动物结束时的最大可能作用(MPE)。 plant内施用吗啡在剂量范围为25.8-257.8 nmol /动物的剂量范围内具有类似剂量的抗痛觉过敏作用,在相似的功效范围内,剂量为257.8 nmol /动物的最大功效为76.0 +/- 12.1%MPE。在测试的剂量范围内,两种化合物均未引起明显的混杂副作用。足底内与各自的激动剂共同给药的NOP受体拮抗剂J-113397和MOP受体拮抗剂纳洛酮选择性和完全地防止了各自的NOP和MOP受体激动剂的抗痛觉过敏作用。这些结果表明,Ro65-6570和吗啡分别激活了外周NOP和MOP受体,从而在糖尿病多发性神经病大鼠中介导了抗痛觉过敏作用。 (C)2015 Elsevier By。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号